Human Immunodeficiency Virus (HIV) Infections (AIDS) accounted for a 6.3% share of the global clinical trials within the Infectious Disease therapy area in 2021, registering a decrease of 6.5% when compared with the last ten-year average of 12.8% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Human Immunodeficiency Virus (HIV) Infections (AIDS)

Industry sponsored trials held a 39.2% share of all the clinical trials for Human Immunodeficiency Virus (HIV) Infections (AIDS) indication in 2021, registering an increase of 5.1% when compared with the ten-year average of 34.1%. Non-industry sponsored trials accounted for a 60.8% share in 2021, marking a decrease of 5.1% over the ten-year average of 65.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Human Immunodeficiency Virus (HIV) Infections (AIDS) trials

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Europe was the top region for industry sponsored Human Immunodeficiency Virus (HIV) Infections (AIDS) trials, accounting for a 43.8% share in 2021, when compared with the five-year average of 34.2% and ten-year average of 41.6%.

Asia-Pacific was at the second position with a 34.4% share in 2021, over the five-year average of 38.6% and ten-year average of 31.7%, followed by North America with a 29.2% share in 2021, as against five-year and ten-year averages of 41.8% and 47.5% respectively.

Middle East and Africa stood fourth with a 9.4% share in 2021, compared with the five-year average of 12.1% and ten-year average of 13.1%, followed by South and Central America with a 6.3% share in 2021, over five-year and ten-year averages of 7.7% and 10.1% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Russia was the top country for industry sponsored Human Immunodeficiency Virus (HIV) Infections (AIDS) trials, accounting for a 37.5% share in 2021, as against the five-year average of 16.9% and ten-year average of 19.9%.

The US held a 27.1% share in 2021, over the five-year average of 40.3% and ten-year average of 45.4%, followed by China with a 20.8% share in 2021, compared with the five-year and ten-year averages of 17.0% and 9.3% respectively.

South Africa held a 9.4% share in 2021, as against the five-year average of 8.5% and ten-year average of 9.6%.

Canada held a 6.3% share in 2021, over the five-year and ten-year averages of 8.2% and 11.3% respectively.

Top regions of non-industry sponsored Human Immunodeficiency Virus (HIV) Infections (AIDS) trials

Middle East and Africa was the top region for non-industry sponsored Human Immunodeficiency Virus (HIV) Infections (AIDS) trials, accounting for a 30.3% share in 2021 when compared with the five-year average of 22.8% and ten-year average of 22.0%.

North America was at the second position with a 25.0% share in 2021, over the five-year and ten-year averages of 36.6% and 37.2% respectively, followed by Asia-Pacific with a 25.0% share in 2021, as against the five-year average of 23.1% and ten-year average of 19.8%.

Europe stood at the fourth position with a 21.7% share in 2021, compared with the five-year average of 23.6% and ten-year average of 27.0%, followed by South and Central America with a 5.9% share in 2021, over the five-year and ten-year averages of 6.2% and 6.2% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for non-industry sponsored Human Immunodeficiency Virus (HIV) Infections (AIDS) trials, accounting for a 20.4% share in 2021, as against the five-year average of 33.2% and ten-year average of 33.7%.

South Africa held a 15.8% share in 2021, over the five-year average of 10.2% and ten-year average of 9.2%, followed by China with a 14.5% share, compared with the five-year and ten-year averages of 10.3% and 7.0% respectively.

Kenya held a 9.2% share in 2021, as against the five-year average of 3.5% and ten-year average of 3.6%.

Uganda held a 9.2% share in 2021, over the five-year average of 7.6% and ten-year average of 6.4%.

Phase I trials lead industry sponsored clinical trials for Human Immunodeficiency Virus (HIV) Infections (AIDS) in 2021

Phase I trials held a 67.3% share of industry sponsored clinical trials for Human Immunodeficiency Virus (HIV) Infections (AIDS) in 2021, over the five-year average of 55.0% and ten-year average of 53.7%.

Phase II trials held a 14.4% share in 2021, as against the five-year average of 16.0% and ten-year average of 15.8%. Phase III trials held a 10.6% share in 2021, compared with the five-year and ten-year averages of 14.3% and 16.9% respectively.

Phase IV trials held a 7.7% share in 2021, over the five-year average of 14.6% and ten-year average of 13.6%.

Phase IV trials lead non-industry sponsored clinical trials for Human Immunodeficiency Virus (HIV) Infections (AIDS) in 2021

Phase IV trials held a 34.8% share of non-industry sponsored clinical trials for Human Immunodeficiency Virus (HIV) Infections (AIDS) in 2021, over the five-year average of 31.6% and ten-year average of 30.1%.

Phase II trials held a 32.3% share in 2021, as against the five-year average of 33.6% and ten-year average of 34.4%. Phase I trials held an 18.6% share, compared with the five-year and ten-year averages of 21.4% and 20.8% respectively.

Phase III trials held a 14.3% share in 2021, over the five-year average of 13.4% and ten-year average of 14.7%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.